Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition

被引:37
作者
Lowes, Lori E. [1 ,2 ]
Allan, Alison L. [2 ,3 ,4 ]
机构
[1] London Hlth Sci Ctr, Special Hematol Flow Cytometry, London, ON, Canada
[2] London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada
[3] Western Univ, Schulich Sch Med & Dent, London, ON, Canada
[4] Lawson Hlth Res Inst, London, ON, Canada
来源
ADVANCES IN CLINICAL CHEMISTRY, VOL 83 | 2018年 / 83卷
关键词
METASTATIC BREAST-CANCER; MULTIPARAMETER FLOW-CYTOMETRY; TRANSCRIPTION FACTOR SNAIL; PROGRESSION-FREE SURVIVAL; REPRESSES E-CADHERIN; MOLECULAR CHARACTERIZATION; PERIPHERAL-BLOOD; HER2; EXPRESSION; VIMENTIN EXPRESSION; COLORECTAL-CANCER;
D O I
10.1016/bs.acc.2017.10.004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The majority of cancer-related deaths result from metastasis, the process by which cancer cells escape the primary tumor site and enter into the blood circulation in order to disseminate to secondary locations throughout the body. Tumor cells found within the circulation are referred to as circulating tumor cells (CTCs), and their detection and enumeration correlate with poor prognosis. The epithelial-to-mesenchymal transition (EMT) is a dynamic process that imparts epithelial cells with mesenchymal-like properties, thus facilitating tumor cell dissemination and contributing to metastasis. However, EMT also results in the downregulation of various epithelial proteins typically utilized by CTC technologies for enrichment and detection of these rare cells, resulting in reduced detection of some CTCs, potentially those with a more metastatic phenotype. In addition to the current clinical role of CTCs as a prognostic biomarker, they also have potential as a predictive biomarker via CTC characterization. However, CTC characterization is complicated by the unknown biological significance of CTCs possessing an EMT-like phenotype, and the ability to capture and understand this CTC subpopulation is an essential step in the utilization of CTCs for patient management. This chapter will review the process of EMT and its contribution to metastasis; discusses current and future clinical applications of CTCs; and describes both traditional and novel methods for CTC enrichment, detection, and characterization with a specific focus on CTCs with an EMT phenotype.
引用
收藏
页码:121 / 181
页数:61
相关论文
共 267 条
[1]   Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis [J].
Aceto, Nicola ;
Bardia, Aditya ;
Miyamoto, David T. ;
Donaldson, Maria C. ;
Wittner, Ben S. ;
Spencer, Joel A. ;
Yu, Min ;
Pely, Adam ;
Engstrom, Amanda ;
Zhu, Huili ;
Brannigan, Brian W. ;
Kapur, Ravi ;
Stott, Shannon L. ;
Shioda, Toshi ;
Ramaswamy, Sridhar ;
Ting, David T. ;
Lin, Charles P. ;
Toner, Mehmet ;
Haber, Daniel A. ;
Maheswaran, Shyamala .
CELL, 2014, 158 (05) :1110-1122
[2]   The systematic study of circulating tumor cell isolation using lithographic microfilters [J].
Adams, Daniel L. ;
Zhu, Peixuan ;
Makarova, Olga V. ;
Martin, Stuart S. ;
Charpentier, Monica ;
Chumsri, Saranya ;
Li, Shuhong ;
Amstutz, Platte ;
Tang, Cha-Mei .
RSC ADVANCES, 2014, 4 (09) :4334-4342
[3]   Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases [J].
Aitken, S. J. ;
Thomas, J. S. ;
Langdon, S. P. ;
Harrison, D. J. ;
Faratian, D. .
ANNALS OF ONCOLOGY, 2010, 21 (06) :1254-1261
[4]   Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients [J].
Aktas, Bahriye ;
Mueller, Volkmar ;
Tewes, Mitra ;
Zeitz, Julia ;
Kasimir-Bauer, Sabine ;
Loehberg, Christian R. ;
Rack, Brigitte ;
Schneeweiss, Andreas ;
Fehm, Tanja .
GYNECOLOGIC ONCOLOGY, 2011, 122 (02) :356-360
[5]   Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients [J].
Aktas, Bahriye ;
Tewes, Mitra ;
Fehm, Tanja ;
Hauch, Siegfried ;
Kimmig, Rainer ;
Kasimir-Bauer, Sabine .
BREAST CANCER RESEARCH, 2009, 11 (04)
[6]   Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy [J].
Alix-Panabieres, Catherine ;
Pantel, Klaus .
CANCER DISCOVERY, 2016, 6 (05) :479-491
[7]   Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic [J].
Allan, Alison L. ;
Keeney, Andmichael .
JOURNAL OF ONCOLOGY, 2010, 2010
[8]   Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].
Allard, WJ ;
Matera, J ;
Miller, MC ;
Repollet, M ;
Connelly, MC ;
Rao, C ;
Tibbe, AGJ ;
Uhr, JW ;
Terstappen, LWMM .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904
[9]   Genetic and Phenotypic Diversity in Breast Tumor Metastases [J].
Almendro, Vanessa ;
Kim, Hee Jung ;
Cheng, Yu-Kang ;
Goenen, Mithat ;
Itzkovitz, Shalev ;
Argani, Pedram ;
van Oudenaarden, Alexander ;
Sukumar, Saraswati ;
Michor, Franziska ;
Polyak, Kornelia .
CANCER RESEARCH, 2014, 74 (05) :1338-1348
[10]   Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system [J].
Andreopoulou, E. ;
Yang, L. -Y. ;
Rangel, K. M. ;
Reuben, J. M. ;
Hsu, L. ;
Krishnamurthy, S. ;
Valero, V. ;
Fritsche, H. A. ;
Cristofanilli, M. .
INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (07) :1590-1597